AACR19: could HDAC inhibition combat anti-PD-1 resistance in melanoma patients?

According to results from the ENCORE 601 Phase Ib/II clinical trial, a combination of the experimental histone deacetylase (HDAC) inhibitor … Continue reading AACR19: could HDAC inhibition combat anti-PD-1 resistance in melanoma patients?